Skip to main content
Clinical Trials/EUCTR2012-002448-25-GB
EUCTR2012-002448-25-GB
Active, not recruiting
Phase 1

Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients Under Surveillance for Abdominal Aortic Aneurysms to Predict Rupture or Surgical Repair: the MA3RS Trial - MAR3S Trial

niversity of Edinburgh0 sites342 target enrollmentAugust 28, 2012
DrugsRienso

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Edinburgh
Enrollment
342
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 28, 2012
End Date
November 1, 2016
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
niversity of Edinburgh

Eligibility Criteria

Inclusion Criteria

  • 1\. Abdominal aortic aneurysms measuring \=40mm in anteroposterior diameter on ultrasound scanning. 2\. Age \=40 years. Patients with abdominal aortic aneurysms less than 40 years may have a connective tissue disorder and a different aetiology to their disease.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 115
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 234

Exclusion Criteria

  • 1\. Patients expected to undergo imminent elective or emergency surgical or endovascular repair. 2\. Contraindication to magnetic resonance imaging scanning identified from magnetic resonance imaging safety questionnaire, which includes but not limited to: \- intracranial aneurysm clips (except Sugita) or other metallic objects \- history of intra\-orbital metal fragments that have not been removed \- pacemakers, implantable cardiac defibrillators and non\-MR compatible heart valves \- inner ear implants \- history of claustrophobia in MR \- allergy to MRI contrast enhancement agent 3\. Patients refusing or unable to give informed consent 4\. Woman with child\-bearing potential will not be enrolled into the trial (woman who have experienced menarche, are pre\-menopausal, have not been sterilised or who are currently pregnant). 5\. Intercurrent illness including patients with a systemic inflammatory disorder or underlying malignancy (life expectancy \< 2 years). 6\. Renal dysfunction (eGFR \=30 mL/min/1\.73m2\). 7\. Polycythemia. 8\. Contraindication to ferumoxytol (evidence of iron overload, known hypersensitivity to ferumoxytol or its components or anaemia not caused by iron deficiency).

Outcomes

Primary Outcomes

Not specified

Similar Trials